Clinical Trial Update: Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome [NA]

View source ↗

Summary

A completed clinical trial evaluating blood and imaging biomarkers for Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS) in breast cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aromatase Inhibitor-induced Musculoskeletal Syndrome
• Breast Cancer

Snippet

Sponsor: University of Arizona | Conditions: Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS), Breast Cancer | NA | Status: COMPLETED | Results posted: 2023-08-14